Protocol Ledger

NCT06081244 · Phase III · RECRUITING

NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)

Interventional Phase III clinical trial protocol NCT06081244 sponsored by Women's Cancer Study Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-10 Enrollment: 348 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06081244
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)348 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06081244
Protocol FieldVerified Registry Value
NCT IdentifierNCT06081244
Consolidated Lead SponsorWomen's Cancer Study Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment348 participants (ESTIMATED)
Registered Start Date2024-10-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06081244
Hospital Research SiteLocationSite Profile
Universitätsklinikum TübingenTübingen, GermanyOpen Hospital Dossier ->
Universitätsklinikum UlmUlm, GermanyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI